Prognosis
Adderall Supply Delays Likely to Continue for 2-3 Months, Teva Says
- FDA is now listing ADHD drug in shortage on its website
- At least seven companies experiencing supply challenges
Photographer: JB Reed/Bloomberg
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd. will continue to have challenges supplying the popular attention-deficit/hyperactivity disorder drug Adderall for the next two to three months, a company spokesperson said.
The drug has been in short supply since at least August, an issue that started this summer with a labor shortage at Teva, which supplies more Adderall in the US than any other company. Teva sells both the branded and generic products, and demand for the drug is at an all-time high.